Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and/or the need for additional preventive interventions: cumulative data over three stimulation cycles
Language English Country Netherlands Media print-electronic
Document type Journal Article, Multicenter Study, Randomized Controlled Trial
PubMed
30713022
DOI
10.1016/j.rbmo.2018.12.032
PII: S1472-6483(18)30661-8
Knihovny.cz E-resources
- Keywords
- Anti-Müllerian hormone, Follitropin delta, GnRH agonist triggering, OHSS, Ovarian stimulation, Preventive interventions,
- MeSH
- Adult MeSH
- Fertilization in Vitro MeSH
- Follicle Stimulating Hormone, Human administration & dosage therapeutic use MeSH
- Ovulation Induction * adverse effects MeSH
- Data Interpretation, Statistical MeSH
- Sperm Injections, Intracytoplasmic MeSH
- Cryopreservation MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Ovarian Hyperstimulation Syndrome prevention & control MeSH
- Ovary drug effects MeSH
- Recombinant Proteins administration & dosage therapeutic use MeSH
- Risk MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Randomized Controlled Trial MeSH
- Names of Substances
- Follicle Stimulating Hormone, Human MeSH
- follitropin alfa MeSH Browser
- follitropin delta MeSH Browser
- Recombinant Proteins MeSH
RESEARCH QUESTION: Is individualization of dosing with follitropin delta in sequential ovarian stimulation cycles an effective preventive strategy for ovarian hyperstimulation syndrome risk? If so, for which patients does an individualized strategy provide the greatest OHSS risk reduction and/or the need for additional preventive interventions? DESIGN: A secondary analysis of three ovarian stimulation cycles in IVF/intracytoplasmic sperm injection patients included in one randomized, assessor-blinded trial comparing two recombinant FSH preparations (ESTHER-1, NCT01956110), and a second trial in women undergoing up to two additional cycles (ESTHER-2, NCT01956123). Of 1326 women (aged 18-40 years) randomized and treated with follitropin delta or alfa in cycle 1, 513 continued to cycle 2 and 188 to cycle 3. Follitropin delta and alfa doses were maintained/adjusted according to ovarian response in the previous cycle. RESULTS: Individualized dosing with follitropin delta significantly reduced moderate/severe OHSS and/or preventive interventions (P=0.018) versus conventional dosing with follitropin alfa in patients undergoing up to three ovarian stimulation cycles. The greatest benefit was observed in patients in the highest anti-Müllerian hormone (AMH) quartile (P=0.012). On evaluating separately, individualized dosing with follitropin delta significantly lowered the incidences of moderate/severe OHSS (P=0.036) and preventive interventions (P=0.044) versus follitropin alfa. CONCLUSION: An individualized follitropin delta dosing regimen decreased the risk of moderate/severe OHSS as well as the incidence of preventive interventions versus a conventional follitropin alfa regimen. An analysis per AMH quartile indicated that these statistically significant differences are driven mainly by patients with the highest pretreatment AMH levels.
Ferring Pharmaceuticals US Development Parsippany NJ 07054 USA
Global Biometrics Ferring Pharmaceuticals Copenhagen 2300 Denmark
IVF CUBE SE Prague 160 00 Czech Republic
Olive Fertility Centre Vancouver V5Z 3X7 Canada
Science and Medicine Ferring Pharmaceuticals Copenhagen 2300 Denmark
References provided by Crossref.org
